Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.
第一作者:
Michael J,Burke
第一单位:
Department of Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI mmburke@mcw.edu.
作者:
主题词
青少年(Adolescent);成年人(Adult);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);病例对照研究(Case-Control Studies);儿童(Child);儿童, 学龄前(Child, Preschool);环磷酰胺(Cyclophosphamide);阿糖胞苷(Cytarabine);依托泊甙(Etoposide);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);婴儿(Infant);男(雄)性(Male);前体B细胞淋巴母细胞白血病淋巴瘤(Precursor B-Cell Lymphoblastic Leukemia-Lymphoma);预后(Prognosis);前瞻性研究(Prospective Studies);存活率(Survival Rate);青年人(Young Adult)
DOI
10.3324/haematol.2018.204545
PMID
30545921
发布时间
2020-05-20
- 浏览11

Haematologica
986-992页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文